Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (341-350 of 388) with videos related to

Pageof 39
Sort By:
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Cancer|April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaRobert J Motzer, David F McDermott, Bernard Escudier, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
Tumori|June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Pageof 39

Showing results (341-350 of 388) with videos related to

Sort By:
Pageof 39
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Cancer|April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaRobert J Motzer, David F McDermott, Bernard Escudier, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
Tumori|June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Pageof 39